A randomized, double-blind, placebo-controlled, multicenter, binational, phase II trial of immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy. 6. Juni 2014 Kasper, S., Moehler, M., Hegewisch-Becker, S., Overkamp, F., Bechstein, W.O., Kullmann, F., Lang, H., Schoen, M., Smith-Machnow, V., Seehofer, D., Voehringer, M., Geissler, M., Greil, R., Heike, M., Heinemann, V., Lordick, F., Galle, P.R., Schimanski, C.C., 2014. J Clin Oncol 32:5s(suppl; abstr TPS3658). doi: 10.1200/jco.2014.32.15_suppl.tps3658 Abstract Prediction of second-line therapy response by plasma proteins in patients with metastatic renal cell carcinoma. Hölters, S., Ohlmann, C., Bergmann, L., Grünwald, V., Keilholz, U., Staehler, M., Fecher-Trost, C., Schalkowsky, P., Schmerler, D., Junker, K., 2015. Weiterlesen Treatment of Non-transplant patients with multiple myeloma: routine treatment by office-based haematologists in Germany–data from the prospective Tumour Registry Lymphatic Neoplasms (TLN). Knauf, W., Abenhardt, W., Aldaoud, A., Nusch, A., Grugel, R., Münz, M., Hartmann, H., Marschner, N., TLN Study Group, 2014. Oncol Res Treat 37, 635–644. Weiterlesen